Zinecard
Zinecard
Zinecard (/ziːnkɑːrd/), also known as Dexrazoxane, is a medication used to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and will continue to receive doxorubicin therapy to maintain tumor control.
Etymology
The term "Zinecard" is a brand name for the generic drug dexrazoxane. The name "dexrazoxane" is derived from its chemical structure, which includes a dexrotatory ring and a razoxane ring.
Usage
Zinecard is used in conjunction with doxorubicin, an anthracycline chemotherapy drug. It is administered intravenously, usually immediately before doxorubicin administration. The primary purpose of Zinecard is to protect the heart from the toxic effects of doxorubicin, which can cause cardiomyopathy and congestive heart failure.
Mechanism of Action
Zinecard works by inhibiting the formation of free radicals and by chelating iron, both of which are believed to contribute to the cardiotoxicity of doxorubicin. It is thought to interfere with the interaction between doxorubicin and topoisomerase II, an enzyme that is necessary for DNA replication.
Side Effects
Common side effects of Zinecard include nausea, vomiting, and myelosuppression. Less common side effects include allergic reactions, hair loss, and changes in liver function tests.
Related Terms
- Doxorubicin
- Anthracycline
- Cardiomyopathy
- Congestive heart failure
- Free radicals
- Iron
- Topoisomerase II
- Myelosuppression
External links
- Medical encyclopedia article on Zinecard
- Wikipedia's article - Zinecard
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski